Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients

Blood Purification

Volumn 22, Issue 6, 2004, Pages 518-524

  Tsirpanlis, George ^a,f   Dou, Fotini Boufi ^b   Manganas, Stamatios ^b   Chantzis, Konstantinos ^b   Bleta, Aliki ^c   Stamatelou, Kyriaki ^d   Psimenou, Erasmia ^e   Nicolaou, Chrysoula ^b  

^a KAT HOSPITAL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c Dragini Clinic   (Greece)

^d Blue Cross Hospital   (Greece)

^e ALEXANDRA HOSPITAL   (Greece)

^f NONE   (Greece)

Author keywords

C reactive protein; Inflammation in HD patients; Interleukin 10; Interleukin 6; Oxidant stress; Oxidized LDL; Renal failure; Soluble interleukin 6 receptor; Statins

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; FLUINDOSTATIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LOW DENSITY LIPOPROTEIN; STATIN;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; DRUG ACTIVITY; FEMALE; HEMODIALYSIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; C-REACTIVE PROTEIN; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; INDOLES; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPROTEINS, LDL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OXIDATION-REDUCTION; RECEPTORS, INTERLEUKIN-6; RENAL DIALYSIS; TIME FACTORS;

EID: 11244284955     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082166     Document Type: Article

References (20)

1. Cheung AK, Sarnak MJ, Yan G, et al: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58:353-362.
2. Zimmerman J, Herrlinger S, Pruy A, et al: In-flammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
3. Wanner C, Metzger T: C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2003;17(suppl 8):29-32.
4. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors. Atherioscler Thromb Vasc Biol 2001;21:1712-1719.
5. Chang JW, Yang WS, Min WK, et al: Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002;39:1213-1217.
6. Van der Akker, Bredie SJH, Diepenveen SHA, et al: Atorvastatin and simvastatin in patients on hemodialysis: Effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003;16:238-244.
7. Navarro JF, Mora C, Muros M, Garcia-Idoate G: Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron Clin Pract 2003;95:C128-C135.
8. Tsirpanlis G, Bagos P, Ioannou D, et al: The variability and accurate assessment of micro-inflammation in haemodialysis patients. Nephrol Dial Transplant 2004;19:150-157.
9. Samuelsson O, Attman PO, Knight-Gibson C, et al: Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am J Kidney Dis 2002;39:67-75.
10. Ichihara A, Hayashi M, Ryuzaki M, et al: Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002;17:1513-1517.
11. Riesen WF, Engler H, Risch M, et al: Shortterm effects of atorvastatin on C-reactive protein. Eur Heart J 2002; 23:794-799.
12. Jones SA, Horiuchi S, Topley N, et al: The soluble interleukin-6 receptor: Mechanisms of production and implications in disease. FASEB J 2001;15:43-58.
13. Matthews V, Schuster B, Schutze S, et al: Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003;278:38829-38839.
14. Palinski W, Tsimikas S: Immunomodulatory effects of statins: Mechanisms and potential impact on atheriosclerosis. J Am Soc Nephrol 2002;13:1673-1681.
15. Muller-Newen G, Kuster A, Hemman U, et al: Soluble interleukin-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 1998;161:6347-6355.
16. Ancey C, Kuster A, Haan S, et al: A fusion protein of the gp130 and interleukin-6Rα ligandbinding domains acts as a potent interleukin-6 inhibitor. J Biol Chem 2003;278:16968-16972.
17. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, et al: Inhibition of hydroxymethylglutarylcoenzyme A reductase reduces Th1 development and promotes Th2 development. Circ Res 2003;93:948-956.
18. Hulthe J, Fagerberg B: Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Atherioscler Thromb Vasc Biol 2002;22:1162-1167.
19. Sica DA, Gehr TWB: 3-Hydroxy-3-methylglataryl-coenzyme A reductase inhibitors and rhabdomyolysis: Considerations in the renal failure patient. Curr Opin Nephrol Hypertens 2002;11:123-133.
20. Plenge JK, Hernandez TL, Weil KM, et al: Simvastatin lowers C-reactive protein within 14 days. Circulation 2002;106:1447-1452.